NCT01619150 - A Single Center 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Osteoarthritis

Interventions

DRUG

Etoricoxib, followed by placebo (matching tablet, without active ingredient)

Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.

DRUG

Placebo (matching tablet, without active ingredient), followed by etoricoxib

Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.

Trial Locations (1)

CCBR A/S, Aalborg